2026-526343-35-00招募中1 期
A double-blind, randomised, placebo-controlled first-in-human/Phase Ib trial to investigate safety, tolerability, pharmacokinetics, and preliminary efficacy of single and multiple doses of TIR-C 2% cutaneous emulsion in adults with mild to moderate atopic dermatitis
Pharmability AB10 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2026年9月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 52
- 试验地点
- 10
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Anna-Lena Spetz
Scientific
Pharmability AB
研究点 (10)
Loading locations...
相似试验
已完成
1 期
A randomised, placebo-controlled, double-blinded, cross-over, Phase 1 study evaluating the safety and preliminary efficacy of the GLP 1 analogue ROSE-010 on appetite and food intake in overweight and obese subjects.Obesity2023-507758-34-00Rose Pharma Inc.12
招募中
1 期
A double-blind, prospective, randomised, placebo-controlled, single-centre, proof-of-principle trial in healthy volunteers to investigate safety, local tolerability, pharmacokinetics, and pharmacodynamics of Asacaine after topical administration on skin exposed to ultraviolet B radiationTopical pain2026-526022-41-00Auxesis Pharma Holding AB (publ)12
招募中
不适用
A study to test whether different doses of BI 3000202 help people with systemic lupus erythematosus (SLE)Systemic lupus erythematosusjRCT2071250153405
招募中
1 期
A randomised, double-blind, placebo-controlled trial to assess the effects of EP395 following an inhaled endotoxin challenge in healthy adults2024-516187-29-00EpiEndo Pharmaceuticals ehf.65
招募中
1 期
Double-blind, randomized, placebo-controlled pilot clinical trial to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2 macrophages and fat-derived mesenchymal cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV)2023-507700-32-00Peaches Biotech S.L.50